+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 0 - 20Years
All Genders
ID00920972

Reduced-Intensity Stem Cell Transplant Preparation Using Campath, Fludarabine, and Melphalan for Children and Young Adults with Non-Malignant Diseases

Led by Washington University School of Medicine · Updated on 2026-09-16

220

Participants Needed

28

Research Sites

260 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying a reduced-intensity preparative regimen for hematopoietic stem cell transplantation in children and young adults with non-malignant disorders. The goal is to achieve donor cell engraftment using immune suppression without radiation or high-dose chemotherapy, aiming to reduce early and late toxicities. The study also evaluates toxicities within the first 100 days post-transplant and aims to lower rates of acute and chronic graft-versus-host disease GVHD through specific GVHD prevention methods. Participants receive one of several reduced-intensity conditioning treatment plans depending on their disease and donor matching. These regimens include hydroxyurea, Campath-1H, fludarabine, melphalan, and sometimes thiotepa, followed by hematopoietic stem cell infusion. GVHD prophylaxis is provided with different drug schedules for bone marrow or cord blood recipients, including tacrolimus or cyclosporine, mycophenolate mofetil, abatacept, and methotrexate. Treatment timing spans from about 50 days before transplant through various post-transplant days. During the study, participants undergo assessments to measure donor engraftment, blood counts, and toxicities at 100 days and longer-term outcomes such as chronic GVHD, immune system recovery, and survival up to two years after transplant. Researchers monitor toxicity grades and chimerism to evaluate treatment impact. The study involves follow-up laboratory tests, clinical evaluations, and GVHD assessments to understand both short- and long-term effects of the conditioning regimens and transplant outcomes.

CONDITIONS

Brief Title

Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

Research Team

L

Lissy Keller, CCRP

I

Ian Snyder, CCRP

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here